GALT - Galectin Therapeutics GAAP EPS of -$0.19
2023-05-15 09:25:33 ET
- Galectin Therapeutics press release ( NASDAQ: GALT ): Q1 GAAP EPS of -$0.19.
- As of March 31, 2023, the Company had $17.8 million of cash and cash equivalents. Additionally, the Company has $40 million remaining available under a $60 million line of credit provided by its chairman to fund operations. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through at least December 31, 2024.
For further details see:
Galectin Therapeutics GAAP EPS of -$0.19